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Fibronectin promotes VEGF-induced CD34 cell
differentiation into endothelial cells
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Geoffrey Savidge, MD,b and Michael Sobel, MD,a Seattle, Wash; and London, United Kingdom
Background: Adult endothelial progenitor cells (EPC) may be a useful source for engineering the endothelialization of
vascular grafts. However, the optimal factors that promote differentiation of EPCs into endothelium remain to be
elucidated. The goal of this current report was to determine which extracellular matrix (ECM) protein might modulate
or enhance the effects of EPCs on differentiation into mature endothelium.
Methods: Human EPCs (CD34 cells) were cultured in ECM-coated six-well plates in MCDB-131 medium containing
vascular endothelial growth factor (VEGF), insulin-like growth factor1, and basic fibroblast growth factor. After 21
days, differentiated endothelial colonies were confirmed by immunofluorescence for von Willebrand factor (vWF) and
vascular-endothelial (VE)-cadherin and mRNA expression of the endothelial markers Flk-1, vWF, and VE-cadherin. Cell
migration toward the VEGF–matrix protein combinations was also measured.
Results: As judged by positive staining for endothelial markers vWF and VE-cadherin, the combination of VEGF with
fibronectin (FN) produced significantly more endothelial colonies (P < .05) than did collagens I or IV or vitronectin.
Defined fragments of FN did not enhance VEGF-mediated effects. Fibrinogen produced intermediate stimulation of
differentiation. FN also enhanced VEGF-mediated CD34 cell migration. Blockade of 51, but not v3 or v5,
inhibited both VEGF-mediated CD34 cell differentiation and migration.
Conclusions: VEGF and FN together significantly promote the migration and differentiation of CD34 cells. This
synergism is specific to FN and the 51 integrin. Combinations of VEGF and FN may be useful in promoting
differentiation of circulating endothelial progenitors into endothelial cells for tissue engineering. (J Vasc Surg 2004;39:
655-60.)
Clinical Relevance: Treatment of injured or diseased tissues with adult stem cells is a promising approach. In particular,
bone marrow derived circulating endothelial progenitors (CEP’s) have been shown to differentiate into endothelial cells
in vitro and promote tissue revascularization of ischemic limbs and myocardium in vivo. Because of the relative ease of
obtaining CEP’s and as well as its high proliferative rate, CEP’s may have clinical potential for endothelialization of
prosthetic vascular grafts and revascularization of injured myocardium. However, there is a need to better understand the
molecular pathways involved in the proliferation and differentiation of CEP’s to take full advantage of its clinical
potential.
Until recently, differentiation of angioblasts (endothe-
lial progenitors) into endothelial cells (vasculogenesis) was
believed to be restricted to early embryogenesis, whereas
angiogenesis, the sprouting of capillaries from preexisting
blood vessels, occurs both in the developing embryo and in
postnatal life.1,2 However, recent studies have shown the
presence of circulating endothelial progenitor cells (EPC)
in adults that can differentiate into endothelial cells, sug-
gesting that vasculogenesis can occur in the adult.3,4 Evi-
dence suggests that, at least in animal models, EPCs play a
role in new blood vessel formation during wound healing.5
Studies have also shown that circulating EPCs can home in
to sites of ischemia.6 Vascular endothelial growth factor
(VEGF) is known to be essential for the in vitro differentiation
of purified EPCs into mature endothelial cells.4 This observa-
tion is consistent with in vivo studies demonstrating the im-
portance of VEGF in vasculogenesis.7,8 However, the role
that extracellular matrix (ECM) proteins play in the differen-
tiation of EPCs into mature endothelial cells is still unclear.
The interactions between ECM and cells are mediated
by the integrin family of cell surface receptors.9 Binding of
integrins to ECM proteins initiates signals that contribute
to important cellular processes such as cell proliferation,
migration, differentiation, and survival. The formation of
new blood vessels requires signals from both angiogenic
growth factors and ECM. Recent studies have shown that
there is an important synergism between integrins and
growth factor receptors,10 although the exact mechanisms
by which these receptors and ligands cooperate is not
known. In endothelial cells, we recently showed that fi-
bronectin (FN) contains binding sites for VEGF and that
these binding sites were critical for promoting the associa-
tion of the integrin 51 with vascular endothelial growth
factor receptor (VEGFR)2 and for promoting the biologi-
cal responses to VEGF.11
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In the present study, we have investigated the role of
FN in regulating VEGF-induced CD34 cell differentia-
tion into endothelial cells. We hypothesize that optimum
differentiation of CD34 cells into mature endothelial cells
is dependent on the ECM. We show that FN promotes
VEGF-mediated CD34 cell migration and differentia-
tion. Using integrin-blocking antibodies, we also show that
the 51 integrin is involved in regulating CD34 cell
differentiation and migration.
MATERIAL AND METHODS
CD34 differentiation assay. Differentiation of
CD34 cells was carried out as described elsewhere,4 with
minor modifications. Purified human CD34 cells (ob-
tained from BioWhittaker) were cultured in six-well plates.
The plates were coated overnight with ECM proteins (10
g/mL; Chemicon) in phosphate-buffered saline. This
optimal concentration of ECM coating was based on pre-
liminary experiments. After washing plates with phosphate-
buffered saline, the plates were incubated for a further 3
hours in serum-free MCDB-131 medium containing
VEGF (50 ng/mL; R&D systems). Medium was then
discarded, and CD34 cells were seeded at 3 105 cells in
endothelial growth medium consisting of MCDB-131 me-
dium supplemented with VEGF (50 ng/mL), basic fibro-
blast growth factor (10 ng/mL; R&D systems), insulin-like
growth factor-1 (5 ng/mL; R&D systems), the ECM
protein to be tested (10 g/mL), heparin (10 g/mL),
hydrocortisone (1 g/mL), and 15% fetal bovine serum
(stripped of FN and vitronectin by gelatin and antibody
affinity columns). One half of the medium was replaced
every 3 days. After 3 weeks, endothelial cell colonies were
identified by their characteristic morphology and by immu-
nostaining for von Willebrand factor (vWF, Dako) and
vascular-endothelial (VE) cadherin (Santa Cruz).
CD34 migration. Migration assays were performed
with some modifications as described elsewhere,12 with
6.5-mm, 5-m–pore size Transwells (Costar). ECM pro-
teins (50 g/mL) in assay medium (600 L) were placed
into 24-well plates together with VEGF (50 ng/mL) and
incubated for 30 minutes at 37°C. CD34 cells were
washed twice in MCDB-131/0.25% bovine serum albumin
(assay medium) and were resuspended in assay medium to
a final concentration of 1  106 cells/mL. One hundred
microliters of cell suspension was then added to each Trans-
well and placed on the 24-well plate, where it was incubated
for 4 hours. Cells migrating to the underside of the mem-
brane were fixed in 2% paraformaldehyde and stained with
crystal violet. Migrated cells were quantified by eluting dye
with 10% acetic acid and reading absorbance at 562 nm.
For studies with integrin-blocking antibodies, CD34 cell
suspensions in assay medium were incubated with indicated
antibodies for 30 minutes at 37°C before adding cells to
Transwells. Antibodies were also added to the bottom well.
Reverse transcription polymerase chain reaction
analysis. RNA was isolated using the RNeasy kit (Qiagen).
RNA were reverse-transcribed and amplified for CD45,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
VEGFR-2, vWF, and VE-cadherin using the Superscript
one-step RT-PCR kit (Life Technologies). Briefly, samples
were reverse-transcribed for 30 minutes at 45°C and pre-
denatured for 2 minutes at 94°C; this was followed by 35
cycles of denaturing (15 seconds at 94°C), annealing (15
seconds at 55°C), and extension (20 seconds at 72°C) and
by 1 cycle of final extension for 5 minutes at 72°C in a final
volume of 25 L. Polymerase chain reaction (PCR) prod-
ucts were loaded and run on ethidium bromide 2% agarose
gels. The sizes of PCR products for Flk-1, vWF, VE-
cadherin, CD45, and GAPDH are 351, 431, 593, 485, and
576 bp, respectively. The primer sequences used for reverse
transcription (RT) PCR were as follows. vWF forward:
5-tggatgagcttttgcagacc-3, reverse: 5-gtgggagccgtcgtgg-
tact-3; VE-cadherin forward: 5-ggatgaccaagtacagc-3, re-
verse: 5-acacactttgggctggtagg-3; Flk-1 forward: 5-gtgat-
tgccatgttcttctg-3, reverse: 5-gaggatcttgagttcagaca-3;
GAPDH forward: 5-atcaccatcttccaggagcg-3, reverse: 5-
gcctgcttcaccaccttctt-3; CD45 forward13: 5-ttcaacttatac-
ccttcgtgtc-3, reverse: 5-cctgctttactttgtccacttc-3.
Statistical analysis. Results are expressed as means 
SD. Statistical significance between control and experimen-
tal groups was determined by one-way ANOVA. A value of
P  .05 was considered significant. Densitometry analysis
was performed by NIH Image 1.3 software.
RESULTS
FN promotes VEGF-induced CD34 differentia-
tion into endothelial cells. Figure 1 shows the number of
endothelial colonies derived from CD34 cell differentia-
tion in response to different ECM. Endothelial colonies
were observed in all the VEGF–ECM protein combinations
tested. However, when CD34 cells were incubated on
VEGF-FN–coated plates, there was more than a five-fold
increase in endothelial colonies, indicating that FN was the
most effective ECM protein. VEGF-fibrinogen–coated
plates also stimulated endothelial colony formation above
that observed for collagen and vitronectin, but not as
effectively as did FN. Cell adhesions to the different ECM
protein were comparable (data not shown). We also tested
whether any FN fragments could support CD34 cell
differentiation. As shown in Fig 1, when used to coat plates,
a mixture of VEGF and FN 120-kDa cell-binding fragment
was not as effective as the intact FN molecule in differenti-
ating CD34 cells into endothelial cells. Adding both the
FN N-terminal 70-kDa and C-terminal 40-kDa peptides to
the VEGF–FN 120-kDa mixture failed to restore endothe-
lial cell differentiation to the levels observed with intact FN.
CD34 colonies express endothelial markers. To
determine whether the endothelial colonies at day 21 ex-
pressed mRNA for endothelial markers, we performed RT-
PCR analysis of RNA extracted from CD34 at day 0 and
after differentiation at day 21. At day 0, CD34 cells
expressed mRNA for CD45 and VEGFR-2 receptors, and
by day 21, mRNA for endothelial markers vWF and VE-
cadherin was also expressed (Fig 2A). Using densitometry
scanning, quantitative analysis of RT-PCR data for day 0
and day 21 endothelial markers is shown in Fig 2B. These
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data further confirm the differentiation of CD34 hemato-
poietic progenitor cells into endothelial cells.
FN promotes VEGF-induced CD34 migra-
tion. We next compared the effect of FN, vitronectin, and
FN fragments on VEGF-mediated CD34 cell migration.
VEGF alone mildly stimulated CD34 cell migration (Fig
3). When VEGF was incubated with FN, migration of
CD34 cell was increased by nearly three-fold. Vitronectin
(VN) or FN fragments alone or in combination with VEGF
did not promote cell migration more then did VEGF alone.
The effect of FN on VEGF-induced CD34 cell differ-
entiation and migration is mediated by the 51 integrin.
To investigate the role of specific integrins on VEGF-FN–
induced CD34 cell differentiation, CD34 cells were
cultured on FN-coated plates in the presence of VEGF and
integrin-blocking antibodies, and endothelial colony for-
mation was measured after 21 days. Antibodies to 51
inhibited endothelial colony formation by 35%, whereas
antibodies to v3 and v5 had no effect (Fig 4A). In
migration assays, antibodies to 51 inhibited VEGF-
induced CD34 cell migration over a FN substrate,
whereas antibodies to v3 and v5 had no effect (Fig
4B).
DISCUSSION
The goal of this study was to determine which ECM
modulated VEGF-mediated CD34 cell migration and
differentiation into mature endothelial cells. We showed
that FN uniquely promoted VEGF-induced CD34 cell
migration and differentiation. The synergistic effect of FN
was most likely mediated through the 51 integrin. These
observations suggest that both FN and VEGF are critical
for promoting differentiation of EPCs into mature endo-
thelial cells and therefore may contribute to the formation
Fig 1. Comparison of ECM proteins on VEGF-induced CD34
differentiation. 3  105 CD34 cells were cultured for 21 days
with endothelial growth medium on ECM-VEGF–coated plates.
The number of endothelial colonies formed was identified by
staining for vWF and VE-cadherin. Results are expressed as mean
 SD (n 	 3). #P  .05 compared with control (15% serum).
Fig 2. RT-PCR analysis for endothelial markers from VEGF-FN–
differentiated CD34 cells. A, RNA was extracted from freshly
isolated CD34 cells (day 0) and VEGF-FN differentiated CD34
cells (day 21) and was analyzed for endothelial-specific markers by
RT-PCR. Data shown are representative of two independent ex-
periments. B, Densitometry analysis of endothelial markers. Data
are expressed as ratio of mRNA levels to gel background. Data are
means  SEM (n 	 2).
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of new endothelium. Indeed, several recent studies using
animal models have shown that EPCs can contribute to
new blood vessel formation.3,5,14,15 As we recently
showed, platelets are an important source of preformed
VEGF-FN complexes.11 It is therefore likely that release of
VEGF-FN complexes after activation of platelets at sites of
injury could stimulate neoendothelialization and blood
vessel growth, either from preexisting vessels (angiogene-
sis) or by promoting differentiation of EPCs into endothe-
lial cells (vasculogenesis).
The CD34/VEGFR-2 cell was recently shown to
generate both hematopoietic and endothelial cells and thus
may represent the hemangioblast.13 There is also evidence
to suggest that EPCs not only express CD34 and VEGFR-2
but also a newly discovered hematopoietic stem cell marker,
AC133.16 Several studies have shown that AC133 progen-
itor cells can be induced to differentiate into endothelial
cells and form blood vessels.17-19 Recently, AC133 progen-
itors were shown to differentiate more efficiently into en-
dothelial cells when plated on FN-coated plates.20
Our finding that both FN and VEGF are important for
CD34 cell differentiation into endothelial cells is consis-
tent with findings from gene deletion studies. Mutant mice
homozygous for null mutations of FN or 51 die in
embryonic development because of a defective vascular
system.21-23 Similarly, inactivation of one single VEGF
allele caused early embryonic death because of a defective
vascular system, whereas homozygous loss of VEGFR-1 or
VEGFR-2 also resulted in early embryonic lethality, be-
cause of impaired development of blood vessels.7,8,24
These studies show the pivotal importance of FN, VEGF,
and their receptors in blood vessel development.
Fig 3. Effect of ECM proteins on VEGF-induced CD34 cell
migration. Migration assays were carried out as described in the
Methods section. The migration rates of CD34 cells to VEGF
and different combinations of ECM proteins were measured after 6
hours. Results are expressed as mean  SD (n 	 3). #P  .05
compared with VEGF or FN alone. Negative control was medium
alone, and positive controls were VEGF or FN.
Fig 4. Inhibition of VEGF-FN–induced CD34 cell differentia-
tion and migration by antibodies to 51. A, CD34 cells were
cultured on FN-VEGF–coated plates in endothelial growth me-
dium containing blocking antibodies for 51, for v3, or for
v5 (5 g/mL). Fresh antibodies were added every 3 days.
Endothelial colonies were determined after 21 days by staining for
vWF and VE-cadherin. Results are expressed as mean  SD (n 	
3). B, Blocking antibodies to 51, v3, or v5 (20 g/mL)
were assessed for inhibition of VEGF-FN–induced CD34 cell
migration. Results are expressed as mean  SD (n 	 3). #P  .05
compared with VEGF-FN.
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FN provides attachment sites for the hematopoietic
stem cell through its interaction with 51 and 41 and
has been shown to mediate stem cell proliferation.25-27
Collaboration between 51 and c-kit was shown to pro-
mote sustained activation of focal adhesion kinase and
extracellular-regulated kinase (Erk), which enhanced ery-
throid progenitor cell survival and proliferation.28 We re-
cently showed that when endothelial cells bind FN and
VEGF, there is collaboration between 51 and
VEGFR-2, resulting in prolonged Erk activation and en-
hanced endothelial cell migration.11 Although not statisti-
cally significant, 51 antibodies inhibited CD34 cell
differentiation by 35% There are two possibilities as to why
antibodies to 51 only partially inhibited CD34 cell
differentiation by 35%. First, because the differentiation
assay is over 21 days, it is possible that insufficient 51
blocking antibodies were used. Second, it is also possible
that the 41 integrin may be involved in CD34 cell
differentiation. Binding of FN to 51 and 41 can have
opposing effects on hematopoietic stem cells. For example,
ligation of FN to 51 promoted cell proliferation and
survival, whereas to 41, it induced cell death.28 A recent
study showed that adhesion and migration of activated
CD34 cells on a substrate of FN was mediated through
the 51 integrin, whereas adhesion and migration of
quiescent CD34 cells was mediated by 41.29 In our
study, we observed significant inhibition of VEGF-induced
CD34 cell migration using antibodies to 51.
Not collagen, nor VN, nor FN fragments significantly
enhanced VEGF biologic responses. This supports our
theory that the synergism between FN and VEGF arises
because they form a complex of ligands that coordinately
bind their cognate receptors. Collagen and VN are ineffec-
tive because they do not bind VEGF.11 Mixtures of FN
fragments including both the integrin and VEGF-binding
domains were not effective either. One explanation for this
is that the integrin and VEGF-binding domains must be
physically connected for FN to “chaperone” and support
the sustained binding of VEGF to VEGFR-2, while engag-
ing the 51 integrin at the same time.
Among the common ECM proteins, our studies have
shown that a combination of FN and VEGF is superior in
promoting differentiation of EPCs into endothelial cells
and that fibrinogen has an intermediate effect. Fibrinogen
was recently shown to directly interact with VEGF.30 This
suggests that like FN, interaction between fibrinogen and
VEGF may induce specific integrin signaling that enhances
VEGF biological activity. Future studies investigating inte-
grin–FN interactions in EPCs and studies to define the
specific molecular interactions between VEGF and ECM
proteins will be needed to fully understand the specificity
and mechanisms of these interactions.
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